Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma | |
Wu Bin[1]; Zhang Qiang[2]; Sun Jie[3] | |
刊名 | Journal for immunotherapy of cancer
![]() |
2018 | |
卷号 | 6页码:124 |
关键词 | Cost-effectiveness Ipilimumab Nivolumab Renal cell carcinoma Sunitinib |
ISSN号 | 2051-1426 |
URL标识 | 查看原文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/2170261 |
专题 | 上海大学 |
作者单位 | 1.[1]Medical Decision and Economic Group, Department of Pharmacy, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. 2.[2]Department of Clinical Oncology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. 3.[3]Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. scilwsjtu-sunjie@yahoo.com. |
推荐引用方式 GB/T 7714 | Wu Bin[1],Zhang Qiang[2],Sun Jie[3]. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma[J]. Journal for immunotherapy of cancer,2018,6:124. |
APA | Wu Bin[1],Zhang Qiang[2],&Sun Jie[3].(2018).Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.Journal for immunotherapy of cancer,6,124. |
MLA | Wu Bin[1],et al."Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma".Journal for immunotherapy of cancer 6(2018):124. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论